LY2189102 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 2 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2005-002660-29-HU (EUCTR) | 20/04/2007 | 08/11/2005 | A Phase 1b/2 Multiple-Dose Safety and Pharmacokinetic/Pharmacodynamic Study of LY2189102 in Patients with Rheumatoid Arthritis | A Phase 1b/2 Multiple-Dose Safety and Pharmacokinetic/Pharmacodynamic Study of LY2189102 in Patients with Rheumatoid Arthritis | Rheumatoid Arthritis | Product Name: Anti IL-1ß antibody Product Code: LY2189102 Other descriptive name: Anti IL-1ß antibody, subclass IgG4 | Eli Lilly and Company Limited | NULL | Not Recruiting | Female: yes Male: yes | 135 | Phase 1 | Hungary;Spain | ||
| 2 | NCT00380744 (ClinicalTrials.gov) | November 2005 | 22/9/2006 | A Safety and Pharmacokinetics Study in Participants With Rheumatoid Arthritis | A Phase 1b/2 Multiple-Dose Safety Study and Pharmacokinetic/ Pharmacodynamic Study of LY2189102 in Patients With Rheumatoid Arthritis | Arthritis, Rheumatoid | Drug: LY2189102;Drug: placebo | Eli Lilly and Company | NULL | Completed | 18 Years | 75 Years | All | 121 | Phase 1/Phase 2 | United States;Poland;Argentina;Hungary;Spain |